# A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies

> **NCT04244552** · PHASE1 · TERMINATED · sponsor: **Atreca, Inc.** · enrollment: 87 (actual)

## Conditions studied

- Breast Cancer
- Colorectal Cancer
- Ovarian Cancer
- Non-Small Cell Lung Cancer
- Acral Lentiginous Melanoma
- Head and Neck Squamous Cell Carcinoma
- Hepatocellular Carcinoma
- Esophageal Squamous Cell Carcinoma
- Urothelial Carcinoma
- DMMR Colorectal Cancer
- MSI-H Colorectal Cancer
- Melanoma
- Platinum-Resistant Primary Peritoneal Carcinoma
- Platinum-Resistant Fallopian Tube Carcinoma
- Platinum-Resistant Epithelial Ovarian Cancer
- Triple Negative Breast Cancer

## Interventions

- **BIOLOGICAL:** ATRC-101
- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Pegylated liposomal doxorubicin (PLD)

## Key facts

- **NCT ID:** NCT04244552
- **Lead sponsor:** Atreca, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-02-11
- **Primary completion:** 2023-11-01
- **Final completion:** 2023-11-01
- **Target enrollment:** 87 (ACTUAL)
- **Why stopped:** Sponsor Decision
- **Last updated:** 2023-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04244552

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04244552, "A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04244552. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*